Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.

Autor: Wille K; University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany., Huenerbein K; University Institute for Anesthesiology, Intensive Care and Emergency Medicine, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany., Jagenberg E; University Institute for Anesthesiology, Intensive Care and Emergency Medicine, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany., Sadjadian P; University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany., Becker T; University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany., Kolatzki V; University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany., Meixner R; Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany., Marchi H; Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany.; Bielefeld University, Bielefeld, Germany., Fuchs C; Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany.; Bielefeld University, Bielefeld, Germany., Griesshammer M; University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2022 Feb; Vol. 108 (2), pp. 154-162. Date of Electronic Publication: 2021 Nov 10.
DOI: 10.1111/ejh.13721
Abstrakt: In patients with bcr-abl-negative myeloproliferative neoplasms (MPN), concerns are often raised about the use of anticoagulants because of an increased bleeding risk. However, there are few MPN studies focusing on bleeding. To investigate bleeding complications in MPN, we report our retrospective, single-center study of 829 patients with a median follow-up of 5.5 years (range: 0.1-35.6). A first bleeding event occurred in 143 of 829 patients (17.2%), corresponding to an incidence rate of 2.29% per patient/year. During the follow-up period, one out of 829 patients (0.1%) died due to bleeding. Regarding anticoagulation, most bleeding occurred in patients on antiplatelet therapies (60.1%), followed by patients on anticoagulation therapies (20.3%) and patients not on anticoagulation (19.6%). In multivariate analysis, administration of antiplatelet (HR 2.31 [1.43, 3.71]) and anticoagulation therapies (HR 4.06 [2.32, 7.09]), but not age, gender or mutation status, was associated with an increased bleeding risk. Comparing the "probability of bleeding-free survival" between the MPN subtypes, no significant difference was observed (p = 0.91, log-rank test). Our retrospective study shows that antiplatelet and anticoagulation therapies significantly increase the risk of bleeding in MPN patients without affecting mortality. However, there is no reason to refrain from guideline-conform primary or secondary anticoagulation in MPN patients.
(© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje